News from brand institute, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

May 19, 2022, 10:00 ET Hyundai Updates Award Winning Venue® SUV for 2022

Brand Institute is proud to announce having worked with Hyundai Motor Company in developing the brand name Venue®. Hyundai's Venue® recently received ...

May 04, 2022, 10:00 ET FDA Approves Orphalan's CUVRIOR™ (trientine tetrahydrochloride), the first treatment for Wilson's disease in over five decades

Brand Institute is proud to announce working with rare disease specialist, Orphalan, in developing the brand name CUVRIOR™, approved by the United...

May 02, 2022, 04:00 ET FDA genehmigt Alymsys® (bevacizumab-maly), ein von mAbxience entwickeltes Biosimilar von Bevacizumab

May 02, 2022, 04:00 ET La FDA aprueba Alymsys® (bevacizumab-maly), un biosimilar de Bevacizumab desarrollado por mAbxience

May 02, 2022, 04:00 ET FDA aprova Alymsys® (bevacizumabe-maly), biossimilar do Bevacizumab desenvolvido pela mAbxience

May 02, 2022, 04:00 ET La FDA aprueba Alymsys® (bevacizumab-maly), un biosimilar de Bevacizumab desarrollado por mAbxience

May 02, 2022, 04:00 ET La FDA approuve Alymsys® (bevacizumab-maly), un biosimilaire du bévacizumab développé par mAbxience

Apr 25, 2022, 10:15 ET FDA Approves TLANDO® (testosterone undecanoate), an Oral Treatment for Testosterone Replacement Therapy by Antares Pharma, Inc., developed by Lipocine Inc.

Brand Institute is proud to announce working with Lipocine Inc. in developing the brand name TLANDO®, approved by the Food and Drug Administration...

Apr 19, 2022, 17:29 ET Fernando González Díaz diseñará la nueva oficina corporativa de Brand Institute en Puerto Rico

Apr 19, 2022, 10:00 ET Fernando González Díaz to Design Brand Institute's New Corporate Office in Puerto Rico

As Brand Institute expands its operations in San Juan, Puerto Rico, it is proud to announce that it has enlisted Fernando González Díaz, Founder &...

Apr 18, 2022, 15:00 ET FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxience

Brand Institute is proud to announce its successful partnership with Amneal Pharmaceuticals in developing the brand name ALYMSYS®, under which the...

Feb 22, 2022, 10:00 ET Maxim Biomedical's ClearDetect™ COVID-19 Antigen Home Test Receives Emergency Use Authorization (EUA) from the U.S. FDA

Brand Institute is proud to announce its successful partnership with Maxim Biomedical (MaximBio) in naming their MaximBio ClearDetect™ COVID-19...

Feb 03, 2022, 10:00 ET Carlos Beltrán Baseball Academy (CBBA) Partners with Global Naming Agency Brand Institute

Brand Institute is proud to announce its support and enthusiastic patronage of the Carlos Beltrán Baseball Academy (CBBA), a prestigious high school...

Feb 01, 2022, 10:30 ET FDA Approves SPIKEVAX®, Moderna's mRNA COVID-19 Vaccine

Brand Institute is proud to announce its successful partnership with Moderna in naming their FDA-approved COVID-19 vaccine: SPIKEVAX®, the second...

Jan 24, 2022, 10:00 ET Brand Institute Appoints William (Bill) Johnson to Co-Chief Executive Officer & President

Brand Institute is pleased to announce the appointment of William (Bill) Johnson to the role of Co-Chief Executive Officer and President. Mr. Johnson ...

Dec 22, 2021, 10:00 ET FDA Approves TEZSPIRE™ (tezepelumab-ekko), AstraZeneca and Amgen's First-in-Class Treatment for Severe Asthma

Brand Institute is proud to announce its successful partnership with AstraZeneca and Amgen in naming TEZSPIRE™, the first and only biologic to...

Dec 21, 2021, 15:10 ET EMA genehmigt NUVAXOVID®, den Covid-19-Impfstoff von Novavax

Dec 21, 2021, 15:07 ET L'EMA approuve NUVAXOVID®, vaccin contre la COVID-19 de Novavax

Dec 21, 2021, 09:51 ET La EMA aprueba NUVAXOVID®, la vacuna COVID-19 de Novavax

Dec 13, 2021, 10:00 ET FDA Approves Allergan's VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First Eye Drop Approved to Treat Age-Related Presbyopia in Adults

Brand Institute is proud to announce its successful partnership with Allergan, Inc., an AbbVie company, in naming VUITY™, the first and only...

Dec 10, 2021, 10:00 ET FDA Issues Emergency Use Authorization for AstraZeneca’s EVUSHELD™ (tixagevimab co-packaged with cilgavimab), the First Antibody Therapy Authorized in the U.S. for Pre-Exposure Prophylaxis of COVID-19

Brand Institute is proud to announce its successful partnership with AstraZeneca in developing the brand name EVUSHELD™ and assisting with the...

Dec 08, 2021, 20:39 ET La MHRA approuve XEVUDY® (sotrovimab), le traitement par anticorps monoclonal de GlaxoSmithKline et Vir Biotechnology pour les patients atteints de COVID-19

Dec 08, 2021, 12:41 ET MHRA genehmigt XEVUDY® (Sotrovimab), den monoklonalen Antikörper von GlaxoSmithKline und Vir Biotechnology zur Behandlung von Patienten mit Covid-19

Dec 07, 2021, 23:34 ET MHRA aprueba XEVUDY®, de GlaxoSmithKline y Vir Biotechnology para pacientes con COVID‑19

Dec 07, 2021, 10:00 ET MHRA Approves XEVUDY® (sotrovimab), GlaxoSmithKline and Vir Biotechnology's Monoclonal Antibody Treatment for Patients with COVID‑19

Brand Institute is proud to announce its successful partnership with GlaxoSmithKline and Vir Biotechnology in developing the brand name XEVUDY®, a...